U.S. Specialty Stores Stock News

What PROG Holdings’ Recent Performance Signals for Investors With no single headline event setting the tone, interest in PROG Holdings (PRG) today is largely about how its recent share performance, profitability and size stack up for investors watching the diversified financials space. See our latest analysis for PROG Holdings. Recent momentum has been positive, with a 30 day share price return of 11.28% contributing to a year to date share price return of 26.32%. The 1 year total shareholder...

If you are wondering whether CoreCivic is priced attractively today, this article will walk through how its current share price stacks up against a range of valuation checks. The stock last closed at US$17.17, with recent returns of a 7.5% decline over 7 days, an 8.0% decline over 30 days, a 9.7% decline year to date and a 5.5% decline over 1 year, while the 3 year and 5 year returns stand at 75.0% and 123.9% respectively. Recent coverage of CoreCivic has focused on its role in the U.S...

If you are wondering whether Kennametal's current share price lines up with its real worth, this article will walk through what the numbers suggest and what that could mean for you. With the stock at US$40.03 and returns of 4.1% over 7 days, 16.2% over 30 days, 38.1% year to date and 85.4% over 1 year, many investors are asking whether the recent performance still leaves room for value or reflects a shift in risk perceptions. Recent company updates and industry headlines have kept attention...

Why Xylem’s new buyback is on investors’ radar Xylem (XYL) has drawn fresh attention after its Board authorized a share repurchase program of up to US$1.5b, with no expiration date. This type of move is one many investors watch closely. See our latest analysis for Xylem. At a share price of US$128.26, Xylem has a 30 day share price return of 10.53% decline and a year to date share price return of 6.45% decline. Its 1 year total shareholder return of 1.04% versus a 31.54% total shareholder...

Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial of VK2735, a dual GLP-1 and GIP receptor agonist for obesity. The company is advancing both injectable and oral formulations of VK2735 into late-stage clinical trials. Reduced competition following a rival's clinical setback has increased attention on Viking as a potential acquisition target. Viking Therapeutics, traded as NasdaqCM:VKTX, is drawing fresh interest after reaching full enrollment in its Phase 3...

The recent announcement by the Trump administration of a 15% global tariff under the Trade Act of 1974 reignited trade policy uncertainty and weighed on consumer discretionary names, including MGM Resorts International. For MGM, whose casinos and resorts rely on discretionary travel and entertainment spending, renewed tariff tensions highlight how fast-changing policy can affect demand-sensitive leisure industries without any change in company fundamentals. We’ll now examine how this...

If you are wondering whether Humana's share price now reflects fair value or if the market has swung too far, you are not alone. This article aims to unpack that question clearly. Humana's stock has faced heavy pressure recently, with the price at US$176.06 after a 5.9% decline over the last 7 days, 33.2% over the last month and 33.4% year to date. This has contributed to a 30.0% 1-year return and 63.3% and 51.8% returns over 3 and 5 years respectively. Recent coverage around Humana has...

If you are wondering whether Berkshire Hathaway is still a solid home for long term capital or if the current price is asking too much, the starting point is to understand what you are actually paying for each dollar of its underlying businesses. The stock recently closed at US$493.99, with returns of 1% decline over 7 days, 2.2% over 30 days, a 0.6% decline year to date, roughly flat over 1 year, 62.2% over 3 years and 96.4% over 5 years. This gives you a wide range of time frames to think...

Eli Lilly's orforglipron, an oral GLP-1 therapy, outperformed oral semaglutide in the Phase 3 ACHIEVE-3 trial for adults with type 2 diabetes on metformin. The trial showed greater reductions in blood sugar and body weight, supporting a potential shift toward more convenient oral GLP-1 options. Regulatory submissions for orforglipron are underway in more than 40 countries, signaling a broad global push. Eli Lilly (NYSE:LLY) is adding fresh data on orforglipron at a time when its share price...

Boise Cascade (NYSE:BCC) acquired Holden Humphrey, expanding its distribution presence in the US Northeast. The company opened a new Greenfield Distribution Center in Texas, adding capacity and reach for its Building Materials Distribution segment. Boise Cascade recorded a $6 million legal accrual related to a Lacey Act investigation tied to its distribution business. Boise Cascade is a wood products and building materials distributor that serves dealers, homebuilders, and industrial...

Zscaler and Bharti Airtel have launched an AI and Cyber Threat Research Center in India. The initiative is focused on strengthening national cyber resilience, AI driven threat detection, and skills development. The center is intended to support collaboration between public agencies and private sector partners across India. Zscaler, listed on NasdaqGS:ZS, is tying its cloud security platform more closely to India’s digital infrastructure through this new research center with Bharti Airtel...

TransMedics Group FY 2025 earnings snapshot TransMedics Group (TMDX) closed FY 2025 with fourth quarter revenue of US$160.8 million and basic EPS of US$3.08, alongside trailing twelve month revenue of US$605.5 million and EPS of US$5.60 that frame a much larger full year earnings base. Over the past few quarters, the company has seen revenue range from US$143.5 million to US$160.8 million while quarterly EPS moved between US$0.71 and US$3.08. This gives investors a clearer read on how higher...

Vanda Pharmaceuticals (VNDA) is back on investors’ radar after the U.S. Food and Drug Administration approved BYSANTI tablets for bipolar I disorder and schizophrenia, while an earlier imsidolimab filing for generalized pustular psoriasis also progresses through review. See our latest analysis for Vanda Pharmaceuticals. The recent FDA approvals and filings have coincided with sharp share price moves, with a 37.31% 7 day share price return and 56.23% 90 day share price return, while the 1 year...

First Citizens BancShares Inc. is weighing a potential acquisition of KeyCorp, according to recent reports. The possible deal would combine two U.S. regional banks and add to ongoing consolidation in the sector. KeyCorp, listed as NYSE:KEY, last closed at $21.47. For KeyCorp, ticker NYSE:KEY, this potential takeover interest arrives after a 33.5% return over the past year and a 35.9% return over the past three years. The shares most recently closed at $21.47, with year-to-date performance...

Elliott Investment Management has launched an activist campaign at Norwegian Cruise Line Holdings, calling for board and leadership changes. The firm is pushing for a broad rethink of private island investments, ship deployment decisions, and overall governance. This pressure follows recent CEO and board turnover at Norwegian Cruise Line Holdings, listed as NYSE:NCLH. For investors watching NYSE:NCLH, this push comes as the shares trade around $23.81, with a 14.5% gain over the past 30 days...

Lantheus Holdings recently issued 2026 earnings guidance, projecting revenue between US$1.40 billion and US$1.45 billion, alongside preparations for its upcoming Q4 2025 earnings release. The combination of fresh full-year revenue guidance and an earnings report expected to show a year-on-year revenue decline has sharpened investor focus on how Lantheus manages its radiopharmaceutical portfolio and pricing pressures. We’ll now explore how Lantheus’s new 2026 revenue guidance interacts with...

On February 17, 2026, Sana Biotechnology appointed Brian Piper, M.B.A., as Chief Financial Officer, Executive Vice President, Treasurer, and Principal Financial Officer, ending CEO Steven Harr’s tenure as acting Principal Financial Officer. The move brings a veteran finance leader with extensive public biopharma and IPO experience into Sana’s top ranks, potentially reshaping how the company approaches capital allocation and investor engagement. We’ll explore how bringing in an experienced...

Textron (NYSE:TXT) has declared a quarterly dividend to be paid to shareholders. The company has also filed a shelf registration that would allow it to issue various types of securities in the future. These moves affect both near term shareholder returns and the company’s potential options for raising capital. Textron, the parent company behind businesses in aviation, defense and industrial products, is updating its financial toolkit at the same time it is returning cash to investors. The...

Several recent downgrades have put Freshworks (FRSH) under closer scrutiny, as brokers flag tougher competition and AI related headwinds, even as the company reports solid revenue and free cash flow trends and expands its AI product suite. See our latest analysis for Freshworks. Freshworks shares have come under pressure despite upbeat quarterly results and new AI features, with a 30 day share price return of 39.61% decline and a 1 year total shareholder return of 57.94% decline pointing to...

Recent share performance and business snapshot Rexford Industrial Realty (REXR) has seen its share price move within a mixed range recently, with a small gain of 0.6% over the past day and roughly flat performance over the past week. Over a month, the stock shows a 5.2% decline, widening to a 10.3% decline over the past 3 months. On a 1 year view, the total return stands at a 3.5% decline, while the 3 year total return reflects a 30.2% decline. In the context of this share performance, the...

In its recently reported fiscal Q1, Griffon Corporation delivered results that exceeded expectations, advanced a new joint venture between AMES North America and Venanpri Tools to build a global hand tools and home organization platform, and continued returning cash through share repurchases and its 58th consecutive quarterly dividend. An interesting angle for investors is how Griffon is pairing portfolio reshaping through the AMES–Venanpri joint venture with ongoing buybacks and regular...

Recent share performance and business profile Joby Aviation (JOBY) has drawn investor attention after a mixed stretch for the stock, with a 1 day gain of 1.03% but declines over the past week, month and past 3 months. The US based company is developing an electric vertical takeoff and landing aircraft aimed at aerial ridesharing in the United States and Dubai, supported by an app based booking platform. See our latest analysis for Joby Aviation. At a share price of $9.82, Joby’s recent 30 day...

COPT Defense Properties recently declared a higher regular quarterly dividend of US$0.32 per common share for the first quarter of 2026, payable on April 15 to shareholders of record on March 31, reflecting a 4.9% increase from its prior US$0.305 payout. This dividend increase, alongside upcoming commentary from President & CEO Stephen E. Budorick at Citi’s 2026 Global Property CEO Conference, offers investors fresh insight into how management is balancing income returns with longer-term...

If you are wondering whether ImmunityBio's recent share price action still leaves room for value, this article walks through what the current price might be implying about the business. The stock last closed at US$9.54, with returns of 11.7% over 7 days, 53.6% over 30 days, 372.3% year to date and 218.0% over 1 year, which will naturally raise questions about growth expectations and changing risk perceptions. Recent news around ImmunityBio has focused on its position in the pharmaceuticals...